TY - JOUR
T1 - The effect of frailty on survival in patients with COVID-19 (COPE)
T2 - a multicentre, European, observational cohort study
AU - COPE Study Collaborators
AU - Hewitt, Jonathan
AU - Carter, Ben
AU - Vilches-Moraga, Arturo
AU - Quinn, Terence J.
AU - Braude, Philip
AU - Verduri, Alessia
AU - Pearce, Lyndsay
AU - Stechman, Michael
AU - Short, Roxanna
AU - Price, Angeline
AU - Collins, Jemima T.
AU - Bruce, Eilidh
AU - Einarsson, Alice
AU - Rickard, Frances
AU - Mitchell, Emma
AU - Holloway, Mark
AU - Hesford, James
AU - Barlow-Pay, Fenella
AU - Clini, Enrico
AU - Myint, Phyo K.
AU - Moug, Susan J.
AU - McCarthy, Kathryn
AU - Davey, Charlotte
AU - Jones, Sheila
AU - Lunstone, Kiah
AU - Cavenagh, Alice
AU - Silver, Charlotte
AU - Telford, Thomas
AU - Simmons, Rebecca
AU - Mutasem, Tarik El Jichi
AU - Singh, Sandeep
AU - Paxton, Dolcie
AU - Harris, Will
AU - Galbraith, Norman
AU - Bhatti, Emma
AU - Edwards, Jenny
AU - Duffy, Siobhan
AU - Bisset, Carly
AU - Alexander, Ross
AU - Garcia, Madeline
AU - Sangani, Shefali
AU - Kneen, Thomas
AU - Lee, Thomas
AU - McGovern, Aine
AU - Guaraldi, Giovanni
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background: The COVID-19 pandemic has placed unprecedented strain on health-care systems. Frailty is being used in clinical decision making for patients with COVID-19, yet the prevalence and effect of frailty in people with COVID-19 is not known. In the COVID-19 in Older PEople (COPE) study we aimed to establish the prevalence of frailty in patients with COVID-19 who were admitted to hospital and investigate its association with mortality and duration of hospital stay. Methods: This was an observational cohort study conducted at ten hospitals in the UK and one in Italy. All adults (≥18 years) admitted to participating hospitals with COVID-19 were included. Patients with incomplete hospital records were excluded. The study analysed routinely generated hospital data for patients with COVID-19. Frailty was assessed by specialist COVID-19 teams using the clinical frailty scale (CFS) and patients were grouped according to their score (1–2=fit; 3–4=vulnerable, but not frail; 5–6=initial signs of frailty but with some degree of independence; and 7–9=severe or very severe frailty). The primary outcome was in-hospital mortality (time from hospital admission to mortality and day-7 mortality). Findings: Between Feb 27, and April 28, 2020, we enrolled 1564 patients with COVID-19. The median age was 74 years (IQR 61–83); 903 (57·7%) were men and 661 (42·3%) were women; 425 (27·2%) had died at data cutoff (April 28, 2020). 772 (49·4%) were classed as frail (CFS 5–8) and 27 (1·7%) were classed as terminally ill (CFS 9). Compared with CFS 1–2, the adjusted hazard ratios for time from hospital admission to death were 1·55 (95% CI 1·00–2·41) for CFS 3–4, 1·83 (1·15–2·91) for CFS 5–6, and 2·39 (1·50–3·81) for CFS 7–9, and adjusted odds ratios for day-7 mortality were 1·22 (95% CI 0·63–2·38) for CFS 3–4, 1·62 (0·81–3·26) for CFS 5–6, and 3·12 (1·56–6·24) for CFS 7–9. Interpretation: In a large population of patients admitted to hospital with COVID-19, disease outcomes were better predicted by frailty than either age or comorbidity. Our results support the use of CFS to inform decision making about medical care in adult patients admitted to hospital with COVID-19. Funding: None.
AB - Background: The COVID-19 pandemic has placed unprecedented strain on health-care systems. Frailty is being used in clinical decision making for patients with COVID-19, yet the prevalence and effect of frailty in people with COVID-19 is not known. In the COVID-19 in Older PEople (COPE) study we aimed to establish the prevalence of frailty in patients with COVID-19 who were admitted to hospital and investigate its association with mortality and duration of hospital stay. Methods: This was an observational cohort study conducted at ten hospitals in the UK and one in Italy. All adults (≥18 years) admitted to participating hospitals with COVID-19 were included. Patients with incomplete hospital records were excluded. The study analysed routinely generated hospital data for patients with COVID-19. Frailty was assessed by specialist COVID-19 teams using the clinical frailty scale (CFS) and patients were grouped according to their score (1–2=fit; 3–4=vulnerable, but not frail; 5–6=initial signs of frailty but with some degree of independence; and 7–9=severe or very severe frailty). The primary outcome was in-hospital mortality (time from hospital admission to mortality and day-7 mortality). Findings: Between Feb 27, and April 28, 2020, we enrolled 1564 patients with COVID-19. The median age was 74 years (IQR 61–83); 903 (57·7%) were men and 661 (42·3%) were women; 425 (27·2%) had died at data cutoff (April 28, 2020). 772 (49·4%) were classed as frail (CFS 5–8) and 27 (1·7%) were classed as terminally ill (CFS 9). Compared with CFS 1–2, the adjusted hazard ratios for time from hospital admission to death were 1·55 (95% CI 1·00–2·41) for CFS 3–4, 1·83 (1·15–2·91) for CFS 5–6, and 2·39 (1·50–3·81) for CFS 7–9, and adjusted odds ratios for day-7 mortality were 1·22 (95% CI 0·63–2·38) for CFS 3–4, 1·62 (0·81–3·26) for CFS 5–6, and 3·12 (1·56–6·24) for CFS 7–9. Interpretation: In a large population of patients admitted to hospital with COVID-19, disease outcomes were better predicted by frailty than either age or comorbidity. Our results support the use of CFS to inform decision making about medical care in adult patients admitted to hospital with COVID-19. Funding: None.
UR - http://www.scopus.com/inward/record.url?scp=85087748249&partnerID=8YFLogxK
U2 - 10.1016/S2468-2667(20)30146-8
DO - 10.1016/S2468-2667(20)30146-8
M3 - Article
C2 - 32619408
AN - SCOPUS:85087748249
SN - 2468-2667
VL - 5
SP - e444-e451
JO - The Lancet Public Health
JF - The Lancet Public Health
IS - 8
ER -
